EDAP TMS S.A. Submits U.S. FDA 510(k) Application for Marketing Clearance for Sonolith i-move

LYON, France, Aug. 19, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that it has filed its 510(k) application for marketing clearance with the U.S. Food and Drug Administration (FDA) for its new compact and stand alone lithotripter Sonolith i-move.
MORE ON THIS TOPIC